LU92508I2 - Cabozantinib et toutes les formes thérapeutiquement équivalentes qui en dérivent telles que protégées par le brevet de base, y compris les sels pharmacetuiquement acceptables - Google Patents
Cabozantinib et toutes les formes thérapeutiquement équivalentes qui en dérivent telles que protégées par le brevet de base, y compris les sels pharmacetuiquement acceptables Download PDFInfo
- Publication number
- LU92508I2 LU92508I2 LU92508C LU92508C LU92508I2 LU 92508 I2 LU92508 I2 LU 92508I2 LU 92508 C LU92508 C LU 92508C LU 92508 C LU92508 C LU 92508C LU 92508 I2 LU92508 I2 LU 92508I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- compounds
- pharmacetually
- cabozantinib
- protected
- acceptable salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50618103P | 2003-09-26 | 2003-09-26 | |
US53537704P | 2004-01-09 | 2004-01-09 | |
US57738404P | 2004-06-04 | 2004-06-04 | |
EP04789057A EP1673085B1 (en) | 2003-09-26 | 2004-09-24 | C-met modulators and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
LU92508I2 true LU92508I2 (fr) | 2015-11-02 |
Family
ID=34397024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92508C LU92508I2 (fr) | 2003-09-26 | 2014-07-25 | Cabozantinib et toutes les formes thérapeutiquement équivalentes qui en dérivent telles que protégées par le brevet de base, y compris les sels pharmacetuiquement acceptables |
Country Status (19)
Country | Link |
---|---|
US (14) | US9174947B2 (ja) |
EP (9) | EP2213661B1 (ja) |
JP (14) | JP4638436B2 (ja) |
AT (3) | ATE520403T1 (ja) |
AU (3) | AU2004275842B2 (ja) |
BE (1) | BE2014C055I2 (ja) |
CA (2) | CA2744997A1 (ja) |
CY (3) | CY1111956T1 (ja) |
DK (4) | DK2210607T3 (ja) |
ES (6) | ES2925655T3 (ja) |
HK (5) | HK1141799A1 (ja) |
HR (4) | HRP20110707T1 (ja) |
HU (1) | HUS1400052I1 (ja) |
LU (1) | LU92508I2 (ja) |
NL (1) | NL300678I2 (ja) |
PL (3) | PL2210607T3 (ja) |
PT (2) | PT2210607E (ja) |
SI (4) | SI2210607T1 (ja) |
WO (1) | WO2005030140A2 (ja) |
Families Citing this family (260)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX242553B (es) | 2000-10-20 | 2006-12-06 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
ATE508747T1 (de) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
MXPA06003113A (es) | 2003-09-19 | 2006-06-20 | Astrazeneca Ab | Derivados de quinazolina. |
AU2004275842B2 (en) * | 2003-09-26 | 2010-09-02 | Exelixis Inc. | c-MET modulators and methods of use |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
US7767670B2 (en) | 2003-11-13 | 2010-08-03 | Ambit Biosciences Corporation | Substituted 3-carboxamido isoxazoles as kinase modulators |
AU2005207946A1 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
BRPI0507201A (pt) * | 2004-02-27 | 2008-06-10 | Eisai R & D Man Company Ltd | derivado de piridina e derivado de pirimidina (1) |
EP1809614B1 (en) | 2004-04-08 | 2014-05-07 | TargeGen, Inc. | Benzotriazine inhibitors of kinases |
WO2006024034A1 (en) * | 2004-08-25 | 2006-03-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
CN101001629B (zh) | 2004-09-17 | 2010-05-05 | 卫材R&D管理有限公司 | 药物组合物 |
JP4958785B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体およびステアロイル−CoAデサチュラーゼインヒビターとしてのそれらの使用 |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
WO2006034279A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
TW200624427A (en) | 2004-09-20 | 2006-07-16 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
AR051026A1 (es) | 2004-09-20 | 2006-12-13 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
ES2378772T3 (es) | 2004-10-12 | 2012-04-17 | Astrazeneca Ab | Derivados de quinazolina |
AU2005312048B2 (en) * | 2004-11-30 | 2012-08-02 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
EP1674466A1 (en) * | 2004-12-27 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors |
US7576090B2 (en) * | 2004-12-27 | 2009-08-18 | 4Sc Ag | Benzazole analogues and uses thereof |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
EP1957498B1 (en) * | 2005-05-20 | 2017-02-15 | MethylGene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
MX2007015056A (es) * | 2005-06-02 | 2008-03-11 | Galaxy Biotech Llc | Metodos para el tratamiento de tumores de cerebro con anticuerpos. |
US8541457B2 (en) | 2005-06-03 | 2013-09-24 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors |
JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
NZ566793A (en) | 2005-08-24 | 2010-03-26 | Eisai R&D Man Co Ltd | Novel pyridine derivative and pyrimidine derivative |
TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
US7732613B2 (en) | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007061127A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
AR059246A1 (es) * | 2006-01-30 | 2008-03-19 | Array Biopharma Inc | Compuestos heterobiciclicos de tiofeno y metodos de uso |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
US7723330B2 (en) | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
MX2008013427A (es) | 2006-04-19 | 2008-11-04 | Novartis Ag | Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r. |
WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
DK2018380T3 (da) | 2006-05-19 | 2012-01-23 | Abbott Lab | CNS-aktiverede kondenserede bi-heterocyklisk-substituerede azabicykliske alkanderivater |
US20080004273A1 (en) * | 2006-05-30 | 2008-01-03 | Stephane Raeppel | Inhibitors of protein tyrosine kinase activity |
CN101528702A (zh) * | 2006-06-08 | 2009-09-09 | 阿雷生物药品公司 | 喹啉化合物和使用方法 |
WO2008021781A1 (en) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
EP2062886B1 (en) * | 2006-08-23 | 2011-11-30 | Eisai R&D Management Co., Ltd. | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
CL2007003049A1 (es) | 2006-10-23 | 2008-05-16 | Cephalon Inc Pharmacopeia Drug | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. |
EP2079738A2 (en) * | 2006-10-27 | 2009-07-22 | Glaxo Group Limited | 7-azaindole derivatives as c-met kinase inhibitors |
DK3034075T3 (en) | 2006-11-22 | 2018-10-22 | Incyte Holdings Corp | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASEI INHIBITORS |
AU2007338795B2 (en) * | 2006-12-20 | 2012-07-19 | Amgen Inc. | Substituted heterocycles and methods of use |
WO2008079291A2 (en) * | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
EP2120578B1 (en) * | 2007-01-19 | 2014-11-19 | Xcovery, INC. | Kinase inhibitor compounds |
KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
CA2685967A1 (en) * | 2007-05-21 | 2008-11-21 | Novartis Ag | Csf-1r inhibitors, compositions, and methods of use |
DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
US20110281909A1 (en) | 2007-08-15 | 2011-11-17 | Glaxo Group Limited | Substituted quinoline derivatives as h1 receptor antagonists |
AU2008293038B2 (en) | 2007-08-29 | 2013-08-29 | Mirati Therapeutics, Inc. | Inhibitors of protein tyrosine kinase activity |
EP2218712B1 (en) | 2007-11-09 | 2015-07-01 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
ES2531396T3 (es) | 2008-01-23 | 2015-03-13 | Bristol Myers Squibb Co | Proceso para preparar compuestos de piridinona |
PT2947072T (pt) | 2008-03-17 | 2016-12-06 | Ambit Biosciences Corp | 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas |
US8304427B2 (en) | 2008-04-10 | 2012-11-06 | Taiho Pharmaceutical Co., Ltd. | Acylthiourea compound or salt thereof, and use thereof |
EP2262772B8 (en) | 2008-04-16 | 2013-03-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline derivatives as axl kinase inhibitors |
UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
LT2300455T (lt) | 2008-05-21 | 2017-11-10 | Incyte Holdings Corporation | 2-fluor-n-metil-4-[7-(chinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamido druskos ir su jų gamyba susiję būdai |
NZ602832A (en) | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
US8134000B2 (en) | 2008-07-14 | 2012-03-13 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
WO2010009166A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Oxindolyl inhibitor compounds |
EP2149565A1 (de) * | 2008-07-24 | 2010-02-03 | Bayer Schering Pharma AG | Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen |
WO2010014611A1 (en) | 2008-07-28 | 2010-02-04 | Gilead Colorado, Inc. | Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds |
TW201035017A (en) * | 2008-09-26 | 2010-10-01 | Smithkline Beecham Corp | Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide |
US8293897B2 (en) * | 2008-10-14 | 2012-10-23 | Ning Xi | Compounds comprising a spiro-ring and methods of use |
JP5444365B2 (ja) * | 2008-10-29 | 2014-03-19 | デシフェラ ファーマシューティカルズ,エルエルシー | 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質 |
WO2010056960A1 (en) * | 2008-11-13 | 2010-05-20 | Exelixis Inc. | Methods of preparing quinoline derivatives |
JP2012511017A (ja) * | 2008-12-04 | 2012-05-17 | エグゼリクシス, インコーポレイテッド | キノリン誘導体の調製方法 |
DE102009003975A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Benzothiazolonderivate |
KR102187034B1 (ko) * | 2009-01-16 | 2020-12-04 | 엑셀리시스, 인코포레이티드 | 암 치료용 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
AU2010229147B2 (en) * | 2009-03-21 | 2012-07-05 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
WO2010140092A1 (en) | 2009-06-05 | 2010-12-09 | Pfizer Inc. | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
KR20120031170A (ko) | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 hdac 저해제 화합물 |
US8283357B2 (en) | 2009-06-08 | 2012-10-09 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
EA201200144A1 (ru) * | 2009-07-17 | 2012-08-30 | Экселиксис, Инк. | Кристаллические формы n-[3-фтор-4-({6-(метилокси)-7-[(3-морфолин-4-илпропил)окси]хинолин-4-ил}окси)фенил]-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида |
UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
CN102030705B (zh) * | 2009-09-30 | 2012-12-19 | 上海睿智化学研究有限公司 | 7-苄氧基-6-甲氧基-4-羟基喹啉的合成方法 |
EP2311809A1 (en) * | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
EA021439B1 (ru) | 2009-11-03 | 2015-06-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Хиназолиновые соединения |
AU2010322796A1 (en) * | 2009-11-27 | 2012-07-12 | Proteologics, Ltd. | Quinazolin-4(3A)-one derivatives and methods of use thereof |
DE102009056886A1 (de) | 2009-12-03 | 2011-06-09 | Bayer Schering Pharma Aktiengesellschaft | cMet-Inhibitoren zur Behandlung der Endometriose |
CN102086211B (zh) * | 2009-12-08 | 2013-09-11 | 广东东阳光药业有限公司 | 作为蛋白激酶抑制剂的芳杂环化合物 |
CA2788398C (en) | 2010-02-03 | 2018-02-27 | Incyte Corporation | Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors |
SG184040A1 (en) * | 2010-03-12 | 2012-10-30 | Exelixis Inc | Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
WO2011117741A2 (en) * | 2010-03-26 | 2011-09-29 | EastNets | Mobile remittance computer system and method |
CN102212062B (zh) * | 2010-04-02 | 2015-04-29 | 广东东阳光药业有限公司 | 氨基酯类衍生物及其盐和使用方法 |
US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
CA2800998A1 (en) | 2010-04-29 | 2011-11-10 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
NZ604306A (en) | 2010-05-17 | 2015-02-27 | Incozen Therapeutics Pvt Ltd | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
RU2560683C2 (ru) | 2010-06-25 | 2015-08-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации |
JP2013532627A (ja) | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | cMET阻害剤とHGFおよび/またはcMETに対する抗体との組み合わせ |
SG10201609324UA (en) * | 2010-07-16 | 2017-01-27 | Exelixis Inc | C-met modulator pharmaceutical compositions |
WO2012009723A1 (en) | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
US8664244B2 (en) | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
CN103391772A (zh) * | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性***癌和成骨性骨转移的met和vegf的双重抑制剂 |
KR101882328B1 (ko) | 2010-09-27 | 2018-07-27 | 엑셀리시스, 인코포레이티드 | 거세-저항성 전립선 암 및 골형성성 뼈전이의 치료용 met 및 vegf 이중 억제제들 |
CN103391773A (zh) * | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性***癌和成骨性骨转移的met和vegf的双重抑制剂 |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
US20130252956A1 (en) * | 2010-11-22 | 2013-09-26 | Howard Kallender | Methods of treating cancer |
CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
PL2673262T3 (pl) | 2011-02-10 | 2022-04-11 | Exelixis, Inc. | Sposoby wytwarzania związków chinolinowych i kompozycje farmaceutyczne zawierające takie związki |
AU2012225735B2 (en) | 2011-03-04 | 2016-03-10 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
US20120252840A1 (en) * | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
MX2013012695A (es) * | 2011-05-02 | 2014-03-27 | Exelixis Inc | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
CA2845933C (en) | 2011-09-06 | 2020-06-09 | New York Blood Center, Inc. | Hiv inhibitors |
CN102408411B (zh) * | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
KR20140069133A (ko) | 2011-09-22 | 2014-06-09 | 엑셀리시스, 인코포레이티드 | 골다공증의 치료방법 |
HUE048023T2 (hu) | 2011-10-20 | 2020-05-28 | Exelixis Inc | Eljárás kinolin-származékok elõállítására |
US8843421B2 (en) | 2011-11-01 | 2014-09-23 | Accenture Global Services Limited | Identification of entities likely to engage in a behavior |
CN104039226A (zh) | 2011-11-08 | 2014-09-10 | 埃克塞里艾克西斯公司 | 定量癌症治疗的方法 |
AU2012335737A1 (en) | 2011-11-08 | 2014-06-05 | Exelixis, Inc. | Dual inhibitor of MET and VEGF for treating cancer |
TWI577671B (zh) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
EP2796451B1 (en) * | 2011-12-20 | 2018-08-01 | Wei Qian | Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof |
CN102643268B (zh) * | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | 喹啉类及噌啉类化合物及其应用 |
EP2620869B1 (en) | 2012-01-27 | 2017-11-01 | Optim Corporation | Portable terminal, method, and program of changing user interface |
US9358235B2 (en) * | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
CN107082779A (zh) | 2012-03-30 | 2017-08-22 | 理森制药股份公司 | 作为c‑met 蛋白激酶调节剂的新化合物 |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
WO2013180128A1 (ja) * | 2012-05-28 | 2013-12-05 | 協和発酵キリン株式会社 | 4-[4-(5員環芳香族複素環カルボニルウレイド)フェニルオキシ]キノリン誘導体 |
CN103509024B (zh) * | 2012-06-28 | 2015-10-28 | 上海医药工业研究院 | 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用 |
CN103626761B (zh) * | 2012-08-24 | 2015-07-29 | 上海医药工业研究院 | 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用 |
CN103626762B (zh) * | 2012-08-24 | 2015-07-29 | 上海医药工业研究院 | 苯并吡啶氮杂卓类化合物及其应用 |
TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基-喹啉類 |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
CN103664776B (zh) * | 2012-09-26 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种酪氨酸激酶抑制剂及其中间体的制备方法 |
CN103705521A (zh) * | 2012-09-28 | 2014-04-09 | 韩冰 | 一类治疗脑梗塞的化合物及其用途 |
CN103804382A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
CN103804305A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
CN102977014B (zh) * | 2012-11-05 | 2015-01-07 | 沈阳药科大学 | 新的喹啉类化合物及其用途 |
CN103804381A (zh) * | 2012-11-06 | 2014-05-21 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
CN103800328A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
CN103804361A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
CN103804290A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
CN103804291A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
CN103804298A (zh) * | 2012-11-09 | 2014-05-21 | 韩冰 | 一类治疗青光眼的化合物及其用途 |
CN103800340A (zh) * | 2012-11-09 | 2014-05-21 | 韩冰 | 一类治疗青光眼的化合物及其用途 |
CN103804306A (zh) * | 2012-11-12 | 2014-05-21 | 韩文毅 | 一类治疗糖尿病的化合物及其用途 |
CN103804362A (zh) * | 2012-11-12 | 2014-05-21 | 韩文毅 | 一类治疗糖尿病的化合物及其用途 |
CN103804363A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
CN102964308B (zh) * | 2012-11-30 | 2015-03-18 | 中国药科大学 | 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
CN104755463A (zh) | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | 非晶态形式的喹啉衍生物及其生产方法 |
CN103965104B (zh) * | 2013-01-29 | 2017-09-29 | 正大天晴药业集团股份有限公司 | 一种酪氨酸激酶抑制剂及其中间体的制备方法 |
AU2014220300B2 (en) | 2013-02-21 | 2016-10-13 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
WO2014145693A1 (en) * | 2013-03-15 | 2014-09-18 | Exelixis, Inc. | Metabolites of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
CA2907334C (en) * | 2013-03-15 | 2021-12-07 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
KR20150128863A (ko) * | 2013-03-15 | 2015-11-18 | 에프. 호프만-라 로슈 아게 | RORc 조절제로서 아릴 설파미드 및 설파메이트 유도체 |
BR112015025408A8 (pt) * | 2013-04-04 | 2018-07-10 | Exelixis Inc | combinações de drogas para tratar câncer |
ES2927651T3 (es) | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
CN104109124B (zh) * | 2013-04-19 | 2016-08-31 | 正大天晴药业集团股份有限公司 | 卡博替尼·0.5苹果酸盐的晶体 |
CN104109128B (zh) * | 2013-04-19 | 2016-10-05 | 连云港润众制药有限公司 | 卡博替尼苹果酸盐及其制备方法 |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
CN104370811B (zh) * | 2013-08-15 | 2019-02-12 | 广东东阳光药业有限公司 | 一种喹啉化合物的新晶型及其制备方法 |
DK3039424T3 (da) | 2013-08-28 | 2020-08-31 | Crown Bioscience Inc Taicang | Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse |
CN104628657A (zh) * | 2013-11-06 | 2015-05-20 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
EP3738952A1 (en) | 2014-02-14 | 2020-11-18 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
US11040937B2 (en) | 2014-02-28 | 2021-06-22 | Tohoku University | Amide derivative |
WO2015142928A1 (en) | 2014-03-17 | 2015-09-24 | Exelixis, Inc. | Dosing of cabozantinib formulations |
JP2017516458A (ja) | 2014-03-24 | 2017-06-22 | ジェネンテック, インコーポレイテッド | c−met拮抗剤による癌治療及びc−met拮抗剤のHGF発現との相関 |
EP3906921A1 (en) | 2014-04-25 | 2021-11-10 | Exelixis, Inc. | Method of treating lung adenocarcinoma |
WO2015177758A1 (en) | 2014-05-23 | 2015-11-26 | Mylan Laboratories Ltd | Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base |
CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
US11124481B2 (en) * | 2014-07-31 | 2021-09-21 | Exelixis, Inc. | Method of preparing fluorine-18 labeled Cabozantinib and its analogs |
WO2016022697A1 (en) * | 2014-08-05 | 2016-02-11 | Exelixis, Inc. | Drug combinations to treat multiple myeloma |
EP4089076A1 (en) | 2014-08-28 | 2022-11-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
ES2764440T3 (es) | 2014-09-19 | 2020-06-03 | New York Blood Center Inc | Fenilpirrolcarboxamidas sustituidas con actividad terapéutica en VIH |
EP3227276B1 (en) | 2014-12-02 | 2021-09-01 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
US10398774B2 (en) | 2014-12-09 | 2019-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against AXL |
CA2976325C (en) | 2015-02-25 | 2023-07-04 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
ES2716633T3 (es) | 2015-03-25 | 2019-06-13 | Sandoz Ag | Formas cristalinas de fosfato de cabozantinib e hidrocloruro de cabozantinib |
CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
KR20180018695A (ko) | 2015-06-16 | 2018-02-21 | 가부시키가이샤 프리즘 파마 | 항암제 |
US20170020856A1 (en) * | 2015-06-29 | 2017-01-26 | Ontogenesis, Llc | N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use |
EP3337786B1 (en) * | 2015-08-19 | 2019-12-11 | Sandoz AG | Asymmetric bisamidation of malonic ester derivatives |
CN105218445B (zh) * | 2015-08-25 | 2018-05-22 | 江苏中邦制药有限公司 | 一种酪氨酸激酶抑制剂Foretinib的制备方法 |
CN106543143B (zh) * | 2015-09-22 | 2019-03-22 | 合肥中科普瑞昇生物医药科技有限公司 | 一类新型的flt3激酶抑制剂及其用途 |
MX2018007266A (es) | 2015-12-18 | 2018-11-09 | Ignyta Inc | Combinaciones para el tratamiento del cancer. |
CN105541798B (zh) * | 2016-02-03 | 2018-01-23 | 中国人民解放军第二军医大学 | 具有抗肿瘤活性的喹啉类多靶点激酶抑制剂及其制备方法 |
CN107129465B (zh) * | 2016-02-26 | 2020-06-19 | 中国科学院上海药物研究所 | 芳基胍类化合物及其制备方法和用途 |
EP3436462A1 (en) * | 2016-03-31 | 2019-02-06 | Merck Patent GmbH | Compounds for the inhibition of cyclophilins and uses thereof |
CN109069499A (zh) | 2016-04-15 | 2018-12-21 | 埃克塞里艾克西斯公司 | 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法 |
CN105906568A (zh) * | 2016-04-28 | 2016-08-31 | 西安交通大学 | 一种具有抗肿瘤活性的环丙二酰胺化合物及其制备方法和应用 |
CN106083715A (zh) * | 2016-06-01 | 2016-11-09 | 谢阳 | 一种喹啉、喹唑啉类化合物及其药物组合物和应用 |
CN106008371A (zh) * | 2016-06-24 | 2016-10-12 | 谢阳 | 1-芳基脲基环烷基-1-甲酰胺类化合物及其药物组合物和应用 |
CN107556238A (zh) * | 2016-06-30 | 2018-01-09 | 深圳万乐药业有限公司 | 一种卡博替尼的合成方法 |
WO2018026877A1 (en) | 2016-08-05 | 2018-02-08 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
US10980792B2 (en) * | 2016-09-12 | 2021-04-20 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of Cabozantinib |
CN110437145A (zh) * | 2016-09-13 | 2019-11-12 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
JP2019529476A (ja) | 2016-09-27 | 2019-10-17 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | N−(4−(6,7−ジメトキシキノリン−4−イルオキシ)フェニル)−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法 |
WO2018072614A1 (zh) * | 2016-10-18 | 2018-04-26 | 北京康辰药业股份有限公司 | 一种喹啉基取代的羧酸化合物或其药学上可接受的盐、其药物组合物及应用 |
WO2018102455A1 (en) | 2016-12-01 | 2018-06-07 | Ignyta, Inc. | Methods for the treatment of cancer |
CN106632028B (zh) * | 2016-12-22 | 2019-01-22 | 上海再启生物技术有限公司 | 一种卡博替尼的制备方法 |
CN108329298A (zh) * | 2017-01-17 | 2018-07-27 | 南昌弘益药业有限公司 | 一类喹啉类新化合物制备方法 |
KR102610764B1 (ko) | 2017-01-20 | 2023-12-07 | 엑셀리시스, 인코포레이티드 | 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합 |
CN110312511B (zh) | 2017-02-15 | 2023-10-27 | 大鹏药品工业株式会社 | 医药组合物 |
CN108503650B (zh) * | 2017-02-27 | 2021-02-12 | 北京赛特明强医药科技有限公司 | 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用 |
ES2887261T3 (es) * | 2017-04-27 | 2021-12-22 | Astrazeneca Ab | Compuestos de fenoxiquinazolina y su uso para tratar el cáncer |
KR102611445B1 (ko) * | 2017-05-26 | 2023-12-06 | 엑셀리시스, 인코포레이티드 | N-{4-[(6,7-디메톡시퀴놀린-4-일)옥시]페닐}-n′-(4-플루오로페닐) 시클로프로판-1,1-디카르복스아미드의 염의 결정성 고체 형태, 이들을 만들기 위한 제법, 그리고 이들의 이용 방법 |
CN110678180A (zh) | 2017-06-09 | 2020-01-10 | 埃克塞里艾克西斯公司 | 治疗癌症的液体剂型 |
PE20200296A1 (es) * | 2017-07-14 | 2020-02-06 | Innate Tumor Immunity Inc | Moduladores de nlrp3 |
EP3654952A1 (en) | 2017-07-19 | 2020-05-27 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
SG11202001664VA (en) * | 2017-08-31 | 2020-03-30 | Abbvie Inc | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
WO2019077506A1 (en) | 2017-10-17 | 2019-04-25 | Ignyta, Inc. | PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS |
IL310346A (en) | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Muscarinic acetylcholine M4 receptor antagonists |
KR20200081424A (ko) | 2017-10-31 | 2020-07-07 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m4의 길항제 |
CN109824587A (zh) * | 2017-11-23 | 2019-05-31 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂xjf007及其中间体的制备方法 |
CN109896997A (zh) * | 2017-12-08 | 2019-06-18 | 中国药科大学 | N-酰基苯胺类c-Met激酶抑制剂的制备方法及其用途 |
SG11202005719UA (en) | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
US20190262330A1 (en) * | 2017-12-21 | 2019-08-29 | Exelixis, Inc. | Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
CR20230287A (es) | 2018-01-26 | 2023-07-26 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358) |
BR112020015199A2 (pt) * | 2018-01-26 | 2021-05-04 | Exelixis, Inc. | compostos para o tratamento de distúrbios dependentes de quinase |
WO2019148043A1 (en) * | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
KR20200116945A (ko) | 2018-02-02 | 2020-10-13 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m4의 길항제 |
CN108264482A (zh) * | 2018-02-05 | 2018-07-10 | 南京法恩化学有限公司 | 一种卡博替尼的制备方法 |
PL3750893T3 (pl) | 2018-02-11 | 2023-07-17 | Beijing Scitech-Mq Pharmaceuticals Limited | Związek dioksazoliny, sposób jego wytwarzania oraz jego zastosowania |
WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
WO2019234761A1 (en) | 2018-06-05 | 2019-12-12 | Natco Pharma Limited | An improved process for the preparation of cabozantinib and its pharmaceutically acceptable salts thereof |
TWI787523B (zh) | 2018-06-15 | 2022-12-21 | 漢達生技醫藥股份有限公司 | 達沙替尼十二烷基硫酸鹽之結晶 |
SG11202101060WA (en) * | 2018-08-01 | 2021-02-25 | Agency Science Tech & Res | Bicyclic compounds as kinase modulators, methods and uses thereof |
WO2020042972A1 (zh) * | 2018-08-27 | 2020-03-05 | 北京赛特明强医药科技有限公司 | 脲取代的芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用 |
WO2020075196A1 (en) | 2018-10-11 | 2020-04-16 | Cipla Limited | Polymorphs of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (s)- malate, methods of production and pharmaceutical uses thereof |
CN111303024B (zh) * | 2018-12-12 | 2023-03-28 | 安徽中科拓苒药物科学研究有限公司 | 一种喹啉结构的pan-KIT激酶抑制剂及其用途 |
SG11202105949RA (en) * | 2018-12-13 | 2021-07-29 | Exelixis Inc | Crystalline forms and salt forms of a kinase inhibitor |
JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
US20220213064A1 (en) * | 2019-04-12 | 2022-07-07 | National Health Research Institutes | Heterocyclic compounds as kinase inhibitors for therapeutic uses |
CN111825609A (zh) * | 2019-04-22 | 2020-10-27 | 北京康辰药业股份有限公司 | 化合物晶型、其制备方法、药物组合物以及应用 |
AU2019449809A1 (en) * | 2019-06-03 | 2021-12-16 | Exelixis, Inc. | Crystalline salt forms of a kinase inhibitor |
CN110117254B (zh) * | 2019-06-20 | 2022-05-13 | 江苏君若药业有限公司 | 卡博替尼的制备方法 |
CN112778217B (zh) * | 2019-11-08 | 2024-01-26 | 沈阳化工研究院有限公司 | 一种喹唑啉类化合物及其应用 |
CN111393363B (zh) * | 2020-04-27 | 2022-12-20 | 威海海洋生物医药产业技术研究院有限公司 | 4-苯氧基喹啉并n-磺酰脒类化合物及其制备方法和用途 |
CN113577066B (zh) * | 2020-04-30 | 2022-12-16 | 中国科学院上海药物研究所 | 芳基胍化合物或其药学上可接受的盐的用途 |
IT202000027678A1 (it) | 2020-11-18 | 2022-05-18 | Indena Spa | Dispersioni solide amorfe di cabozantinib-(s)-malato e processi per la loro preparazione |
CA3202761A1 (en) | 2020-11-25 | 2022-06-02 | Nanocopoeia, Llc | Amorphous cabozantinib particles and uses thereof |
TW202239407A (zh) * | 2020-12-17 | 2022-10-16 | 瑞典商阿斯特捷利康公司 | N-(2-(4-氰基四氫噻唑-3-基)-2-側氧基乙基)-喹啉-4-甲醯胺 |
EP4313048A1 (en) * | 2021-03-24 | 2024-02-07 | Biocon Limited | Process for preparation of cabozantinib |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023098853A1 (zh) * | 2021-12-03 | 2023-06-08 | 湖南湘源美东医药科技有限公司 | 卡博替尼共晶及制备方法以及作为药物或在药物制剂中的应用 |
CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
WO2023165948A1 (en) | 2022-03-01 | 2023-09-07 | Synthon B.V. | Cabozantinib salt with l-(+)-tartaric acid and solid forms thereof |
WO2023222946A1 (en) | 2022-05-18 | 2023-11-23 | Fermion Oy | Process for the preparation of cabozantinib |
WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
Family Cites Families (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US506181A (en) | 1893-10-03 | Folding crate | ||
GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
US5123951A (en) * | 1986-03-31 | 1992-06-23 | Rhone-Poulenc Nederland B.V. | Synergistic plant growth regulator compositions |
JPS646261A (en) * | 1987-03-31 | 1989-01-10 | Nisshin Flour Milling Co | 4-thioquinazoline derivative, its production and antiulcer agent containing said derivative as active component |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5034393A (en) * | 1989-07-27 | 1991-07-23 | Dowelanco | Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives |
US5238951A (en) * | 1991-02-01 | 1993-08-24 | E. R. Squibb & Sons, Inc. | Heterocyclic amido prostaglandin analogs |
DE4114733A1 (de) * | 1991-05-06 | 1992-11-12 | Huels Chemische Werke Ag | Verfahren zur herstellung von substituierten malonesteraniliden und malonsaeure-monoaniliden |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
US6498144B1 (en) * | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (ja) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
ATE205724T1 (de) | 1995-06-07 | 2001-10-15 | Smithkline Beecham Biolog | Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freien trägerprotein |
US5650415A (en) * | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
EP0832073B1 (en) * | 1995-06-07 | 2002-01-16 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
JP4009681B2 (ja) * | 1995-11-07 | 2007-11-21 | キリンファーマ株式会社 | 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物 |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
SI0880508T1 (en) * | 1996-02-13 | 2003-10-31 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
JP2000506880A (ja) * | 1996-03-15 | 2000-06-06 | ゼネカ・リミテッド | シンノリン誘導体及びその使用 |
US6107300A (en) * | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
CA2249446C (en) * | 1996-04-12 | 2008-06-17 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
JP4386967B2 (ja) * | 1996-07-13 | 2009-12-16 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物 |
DE69733825T2 (de) * | 1996-09-25 | 2006-06-08 | Astrazeneca Ab | Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
ATE480521T1 (de) * | 1996-10-01 | 2010-09-15 | Kyowa Hakko Kirin Co Ltd | Stickstoff enthaltende heterocyclische verbindungen |
GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
DE69816080T2 (de) | 1997-04-18 | 2004-04-15 | Kirin Beer K.K. | Verfahren zur herstellung von chinolinderivaten |
PT977737E (pt) | 1997-04-22 | 2004-02-27 | Janssen Pharmaceutica Nv | Quino- e quinazolinas antagonistas de crf |
GB9708917D0 (en) * | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ES2289791T3 (es) | 1997-08-22 | 2008-02-01 | Astrazeneca Ab | Derivados de oxindolilquinazolina como inhibidores de la angiogenesis. |
JP4194678B2 (ja) * | 1997-11-28 | 2008-12-10 | キリンファーマ株式会社 | キノリン誘導体およびそれを含む医薬組成物 |
RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
WO1999061428A1 (en) * | 1998-05-28 | 1999-12-02 | Parker Hughes Institute | Quinazolines for treating brain tumor |
JP4516690B2 (ja) * | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | 血管形成阻害活性を有するイソキノリン誘導体 |
KR20010089171A (ko) * | 1998-08-21 | 2001-09-29 | 추후제출 | 퀴나졸린 유도체 |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
WO2000015202A2 (de) | 1998-09-10 | 2000-03-23 | Ipr-Institute For Pharmaceutical Research Ag | Topisch anwendbare mittel |
US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
AU763669B2 (en) | 1998-09-29 | 2003-07-31 | Wyeth Holdings Corporation | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
JP2002526538A (ja) | 1998-10-01 | 2002-08-20 | アストラゼネカ アクチボラグ | 化学化合物 |
ATE294796T1 (de) | 1998-10-08 | 2005-05-15 | Astrazeneca Ab | Chinazolin derivate |
US6344455B1 (en) * | 1998-11-19 | 2002-02-05 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, and irreversible inhibitor of tyrosine kinases |
CA2361057C (en) * | 1999-01-22 | 2010-04-06 | Kazuo Kubo | Quinoline derivatives and quinazoline derivatives |
CA2674803C (en) | 1999-02-10 | 2012-10-09 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
GB9904103D0 (en) * | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6258820B1 (en) * | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
JP2002539262A (ja) | 1999-03-19 | 2002-11-19 | パーカー ヒューズ インスティテュート | キナゾリン化合物製剤および治療におけるその使用 |
RS49836B (sr) | 1999-03-31 | 2008-08-07 | Pfizer Products Inc., | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
GB9910580D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
US6126917A (en) * | 1999-06-01 | 2000-10-03 | Hadasit Medical Research Services And Development Ltd. | Epidermal growth factor receptor binding compounds for positron emission tomography |
PT1731511E (pt) * | 1999-06-21 | 2015-11-13 | Boehringer Ingelheim Pharma | Heterociclos bicíclicos, medicamentos contendo estes compostos, a sua utilização e processos para a sua preparação |
CA2384291A1 (en) * | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
US6759410B1 (en) * | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
CA2392554A1 (en) * | 1999-11-30 | 2001-06-28 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
US20020002169A1 (en) * | 1999-12-08 | 2002-01-03 | Griffin John H. | Protein kinase inhibitors |
AU2223201A (en) * | 1999-12-24 | 2001-07-09 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives and drugs containing the same |
US6525046B1 (en) * | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6977259B2 (en) * | 2000-01-28 | 2005-12-20 | Astrazeneca Ab | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
US6664390B2 (en) | 2000-02-02 | 2003-12-16 | Warner-Lambert Company Llc | Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine |
CA2398754A1 (en) * | 2000-02-07 | 2001-08-09 | Abbott Gmbh & Co. Kg | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
CN1190197C (zh) | 2000-03-13 | 2005-02-23 | 惠氏控股公司 | 氰基喹啉用于制备治疗或抑制结肠息肉药物中的用途 |
US6608048B2 (en) * | 2000-03-28 | 2003-08-19 | Wyeth Holdings | Tricyclic protein kinase inhibitors |
US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
US6627634B2 (en) * | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
CA2413424C (en) * | 2000-06-22 | 2007-10-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
RU2283311C2 (ru) | 2000-06-28 | 2006-09-10 | Астразенека Аб | Замещенные производные хиназолина и их применение в качестве ингибиторов |
EP1174118A1 (de) | 2000-06-28 | 2002-01-23 | Cognis France S.A. | Verwendung von Inulinen und Inulinderivaten |
FR2811658B1 (fr) | 2000-07-17 | 2004-07-02 | Cfpi Nufarm | Reacteur biologique a lit fixe immerge et procede de traitement d'effluents liquides |
JP2002030083A (ja) * | 2000-07-18 | 2002-01-29 | Kirin Brewery Co Ltd | N−(2−クロロ−4−{[6−メトキシ−7−(3−ピリジルメトキシ)−4−キノリル]オキシ}フェニル)−n’−プロピルウレアの二塩酸塩 |
US7427689B2 (en) * | 2000-07-28 | 2008-09-23 | Georgetown University | ErbB-2 selective small molecule kinase inhibitors |
US7115615B2 (en) | 2000-08-21 | 2006-10-03 | Astrazeneca | Quinazoline derivatives |
US6617329B2 (en) * | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
US6740651B2 (en) * | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
DE10042058A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6403580B1 (en) * | 2000-08-26 | 2002-06-11 | Boehringer Ingelheim Pharma Kg | Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6653305B2 (en) * | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US6939866B2 (en) | 2000-10-13 | 2005-09-06 | Astrazeneca Ab | Quinazoline derivatives |
AU2001292138A1 (en) | 2000-10-13 | 2002-04-22 | Astrazeneca Ab | Quinazoline derivatives with anti-tumour activity |
MX242553B (es) * | 2000-10-20 | 2006-12-06 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
JP2004512335A (ja) | 2000-10-25 | 2004-04-22 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
JP2004514718A (ja) | 2000-11-02 | 2004-05-20 | アストラゼネカ アクチボラグ | 抗癌剤としての置換キノリン類 |
WO2002036577A1 (fr) | 2000-11-02 | 2002-05-10 | Nippon Shinyaku Co., Ltd. | Derives quinazoline et medicaments |
US7253184B2 (en) | 2000-11-02 | 2007-08-07 | Astrazeneca Ab | 4-Substituted quinolines as antitumor agents |
US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
US6900220B2 (en) * | 2001-01-02 | 2005-05-31 | Syntex (U.S.A.) Llc | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
WO2002085895A1 (en) | 2001-04-19 | 2002-10-31 | Astrazeneca Ab | Quinazoline derivatives |
MXPA03009662A (es) * | 2001-04-27 | 2004-12-06 | Kirin Brewery | Derivados de quinolina y derivados de quinazolina que tienen grupos azolilo. |
SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
WO2002092578A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
WO2002092577A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
WO2002092579A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
US6734303B2 (en) * | 2001-05-18 | 2004-05-11 | Pfizer Inc. | Process for the production of quinazolines |
DE10125432A1 (de) * | 2001-05-25 | 2002-11-28 | Bayer Ag | Substituierte Benzoylketone |
AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
CN100415720C (zh) * | 2001-06-22 | 2008-09-03 | 麒麟医药株式会社 | 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物 |
KR100397792B1 (ko) * | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법 |
GB0118752D0 (en) * | 2001-08-01 | 2001-09-26 | Pfizer Ltd | Process for the production of quinazolines |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
US20030066060A1 (en) | 2001-09-28 | 2003-04-03 | Ford Richard L. | Cross profile guided optimization of program execution |
EP1447405A4 (en) | 2001-10-17 | 2005-01-12 | Kirin Brewery | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS |
AU2002361577A1 (en) | 2001-10-30 | 2003-05-12 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
GB0128108D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
NZ533118A (en) * | 2001-11-27 | 2006-07-28 | Wyeth Corp | 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases |
GB0129099D0 (en) | 2001-12-05 | 2002-01-23 | Astrazeneca Ab | Chemical compounds |
WO2003047584A1 (en) | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives |
AU2002347336A1 (en) | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Quinoline derivatives |
WO2003049740A1 (en) * | 2001-12-12 | 2003-06-19 | Pfizer Products Inc. | Quinazoline derivatives for the treatment of abnormal cell growth |
EP1456199A1 (en) | 2001-12-12 | 2004-09-15 | Pfizer Products Inc. | Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer |
TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
AU2002361846A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
BRPI0215312B8 (pt) | 2001-12-24 | 2021-05-25 | Astrazeneca Ab | composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto |
WO2003064431A2 (en) | 2002-01-29 | 2003-08-07 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
JP4445753B2 (ja) | 2002-01-29 | 2010-04-07 | グラクソ グループ リミテッド | アミノピペリジン誘導体 |
EP1474420B1 (en) | 2002-02-01 | 2012-03-14 | AstraZeneca AB | Quinazoline compounds |
DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
US20050049267A1 (en) * | 2002-03-01 | 2005-03-03 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
DE10217689A1 (de) | 2002-04-19 | 2003-11-13 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
AU2003235838A1 (en) * | 2002-05-01 | 2003-11-17 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor |
JP4703183B2 (ja) | 2002-07-15 | 2011-06-15 | シンフォニー エボルーション, インク. | 受容体型キナーゼモジュレーターおよびその使用方法 |
CN1688549A (zh) * | 2002-08-23 | 2005-10-26 | 麒麟麦酒株式会社 | 具有TGFβ抑制活性的化合物和含所述化合物的药用组合物 |
GB0219746D0 (en) | 2002-08-23 | 2002-10-02 | Inst Of Ex Botany Ascr | Azapurine derivatives |
ES2294317T3 (es) | 2002-10-21 | 2008-04-01 | Kirin Pharma Kabushiki Kaisha | Sal de n-(2-cloro-4-((6,7-dimetoxi-4-quinolil)oxi)fenil)-n'-(5-metil-3-isoxazolil)urea de forma cristalina. |
JPWO2004039782A1 (ja) * | 2002-10-29 | 2006-03-02 | 麒麟麦酒株式会社 | Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
CA2503371C (en) | 2002-11-04 | 2011-01-11 | Astrazeneca Ab | Quinazoline derivatives as src tyrosine kinase inhibitors |
AU2003300898A1 (en) | 2002-12-13 | 2004-07-09 | Neurogen Corporation | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
PL377686A1 (pl) | 2002-12-18 | 2006-02-06 | Pfizer Products Inc. | Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek |
WO2004058267A1 (en) | 2002-12-23 | 2004-07-15 | Ariad Pharmaceuticals, Inc. | Heterocycles and uses thereof |
WO2004060373A1 (ja) * | 2002-12-27 | 2004-07-22 | Santen Pharmaceutical Co., Ltd. | 滲出型加齢黄斑変性治療剤 |
US8176532B1 (en) * | 2003-03-17 | 2012-05-08 | Sprint Communications Company L.P. | Secure access point for scada devices |
KR100559180B1 (ko) * | 2003-05-20 | 2006-03-14 | 김민서 | 조건부 거래에 따른 전자결제 방법 및 전자결제 서버 |
WO2005003140A1 (en) | 2003-07-02 | 2005-01-13 | Pharmacia & Upjohn Company Llc | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents |
US20070213374A1 (en) | 2003-07-07 | 2007-09-13 | Merck Patent Gmbh | Malonamide Derivatives |
AU2004275842B2 (en) * | 2003-09-26 | 2010-09-02 | Exelixis Inc. | c-MET modulators and methods of use |
AU2005207946A1 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc. | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
JP5368701B2 (ja) * | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | c−Metモジュレーター及び使用方法 |
JP2008537748A (ja) * | 2005-04-06 | 2008-09-25 | エクセリクシス、インコーポレイテッド | c−Metモジュレーター及び使用方法 |
US7594258B2 (en) * | 2005-06-27 | 2009-09-22 | Yahoo! Inc. | Access control systems and methods using visibility tokens with automatic propagation |
US20080004273A1 (en) * | 2006-05-30 | 2008-01-03 | Stephane Raeppel | Inhibitors of protein tyrosine kinase activity |
AU2009300328A1 (en) | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
JP2012511017A (ja) * | 2008-12-04 | 2012-05-17 | エグゼリクシス, インコーポレイテッド | キノリン誘導体の調製方法 |
KR102187034B1 (ko) * | 2009-01-16 | 2020-12-04 | 엑셀리시스, 인코포레이티드 | 암 치료용 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
EA201200144A1 (ru) * | 2009-07-17 | 2012-08-30 | Экселиксис, Инк. | Кристаллические формы n-[3-фтор-4-({6-(метилокси)-7-[(3-морфолин-4-илпропил)окси]хинолин-4-ил}окси)фенил]-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
EP2475390A4 (en) | 2009-09-09 | 2014-01-01 | Quintiles Transnat Corp | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS |
JP5461213B2 (ja) | 2010-01-29 | 2014-04-02 | 三洋電機株式会社 | 空気調和装置の室外ユニット |
US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
US20120252840A1 (en) * | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
-
2004
- 2004-09-24 AU AU2004275842A patent/AU2004275842B2/en not_active Ceased
- 2004-09-24 AT AT10160517T patent/ATE520403T1/de active
- 2004-09-24 EP EP10160518A patent/EP2213661B1/en active Active
- 2004-09-24 DK DK10160517.8T patent/DK2210607T3/da active
- 2004-09-24 ES ES17190013T patent/ES2925655T3/es active Active
- 2004-09-24 PL PL10160517T patent/PL2210607T3/pl unknown
- 2004-09-24 JP JP2006528265A patent/JP4638436B2/ja not_active Expired - Fee Related
- 2004-09-24 DK DK11179941.7T patent/DK2392564T3/da active
- 2004-09-24 EP EP11179942.5A patent/EP2392565B1/en active Active
- 2004-09-24 WO PCT/US2004/031523 patent/WO2005030140A2/en active Application Filing
- 2004-09-24 SI SI200431754T patent/SI2210607T1/sl unknown
- 2004-09-24 PT PT10160517T patent/PT2210607E/pt unknown
- 2004-09-24 PL PL10160518T patent/PL2213661T3/pl unknown
- 2004-09-24 AT AT04789057T patent/ATE532782T1/de active
- 2004-09-24 EP EP11179944.1A patent/EP2409704B1/en active Active
- 2004-09-24 DK DK11179942.5T patent/DK2392565T3/da active
- 2004-09-24 AT AT10160518T patent/ATE517091T1/de active
- 2004-09-24 CA CA2744997A patent/CA2744997A1/en not_active Abandoned
- 2004-09-24 PT PT10160518T patent/PT2213661E/pt unknown
- 2004-09-24 ES ES10160517T patent/ES2371383T3/es active Active
- 2004-09-24 EP EP04789057A patent/EP1673085B1/en active Active
- 2004-09-24 CA CA2537812A patent/CA2537812C/en active Active
- 2004-09-24 PL PL11179942T patent/PL2392565T3/pl unknown
- 2004-09-24 ES ES11179944.1T patent/ES2651730T3/es active Active
- 2004-09-24 SI SI200432122T patent/SI2392564T1/sl unknown
- 2004-09-24 EP EP17190013.7A patent/EP3329918B1/en active Active
- 2004-09-24 ES ES11179941.7T patent/ES2436888T3/es active Active
- 2004-09-24 EP EP13151957.1A patent/EP2609919A3/en not_active Withdrawn
- 2004-09-24 EP EP13151945.6A patent/EP2612853A1/en not_active Withdrawn
- 2004-09-24 SI SI200431746T patent/SI2213661T1/sl unknown
- 2004-09-24 EP EP11179941.7A patent/EP2392564B1/en active Active
- 2004-09-24 SI SI200432145T patent/SI2392565T1/sl unknown
- 2004-09-24 ES ES11179942.5T patent/ES2466818T3/es active Active
- 2004-09-24 ES ES10160518T patent/ES2369652T3/es active Active
- 2004-09-24 EP EP10160517A patent/EP2210607B1/en active Active
- 2004-09-24 DK DK10160518.6T patent/DK2213661T3/da active
-
2006
- 2006-10-26 US US11/586,751 patent/US9174947B2/en active Active
-
2007
- 2007-05-24 US US11/753,514 patent/US8067436B2/en active Active
- 2007-05-24 US US11/753,503 patent/US8476298B2/en not_active Expired - Fee Related
- 2007-05-24 US US11/753,462 patent/US8178532B2/en active Active
-
2009
- 2009-02-26 US US12/393,806 patent/US7579473B2/en active Active
-
2010
- 2010-07-12 JP JP2010158337A patent/JP5325173B2/ja not_active Expired - Fee Related
- 2010-07-12 JP JP2010158334A patent/JP5325172B2/ja active Active
- 2010-07-12 JP JP2010158335A patent/JP5185331B2/ja active Active
- 2010-07-12 JP JP2010158336A patent/JP5185332B2/ja not_active Expired - Fee Related
- 2010-07-27 AU AU2010204461A patent/AU2010204461B2/en active Active
- 2010-07-27 AU AU2010204459A patent/AU2010204459B2/en not_active Ceased
- 2010-08-27 HK HK10108175.8A patent/HK1141799A1/xx unknown
- 2010-10-06 HK HK10109531.5A patent/HK1143068A1/xx not_active IP Right Cessation
- 2010-10-25 US US12/911,442 patent/US20110077233A1/en not_active Abandoned
- 2010-11-16 JP JP2010256317A patent/JP2011042686A/ja not_active Withdrawn
-
2011
- 2011-09-30 US US13/249,815 patent/US8497284B2/en active Active
- 2011-10-05 HR HR20110707T patent/HRP20110707T1/hr unknown
- 2011-10-19 CY CY20111100990T patent/CY1111956T1/el unknown
- 2011-11-02 HR HR20110810T patent/HRP20110810T1/hr unknown
- 2011-11-14 CY CY20111101096T patent/CY1112056T1/el unknown
-
2012
- 2012-03-22 US US13/427,093 patent/US20120184523A1/en not_active Abandoned
- 2012-05-22 HK HK12105023.6A patent/HK1164313A1/xx unknown
- 2012-05-22 HK HK12105022.7A patent/HK1164312A1/xx not_active IP Right Cessation
-
2013
- 2013-05-07 US US13/888,592 patent/US20140155378A9/en not_active Abandoned
- 2013-06-27 US US13/928,977 patent/US20140155396A1/en not_active Abandoned
- 2013-12-26 JP JP2013268454A patent/JP5694501B2/ja active Active
- 2013-12-26 JP JP2013268455A patent/JP2014055191A/ja active Pending
- 2013-12-26 JP JP2013268453A patent/JP2014074059A/ja not_active Ceased
-
2014
- 2014-01-07 HR HRP20140012TT patent/HRP20140012T1/hr unknown
- 2014-06-13 HR HRP20140563TT patent/HRP20140563T1/hr unknown
- 2014-07-25 LU LU92508C patent/LU92508I2/xx unknown
- 2014-07-31 NL NL300678C patent/NL300678I2/nl unknown
- 2014-09-03 CY CY2014037C patent/CY2014037I2/el unknown
- 2014-09-10 BE BE2014C055C patent/BE2014C055I2/fr unknown
- 2014-09-16 HU HUS1400052C patent/HUS1400052I1/hu unknown
-
2015
- 2015-04-22 JP JP2015087327A patent/JP2015131859A/ja not_active Withdrawn
- 2015-09-08 US US14/847,801 patent/US20150376133A1/en not_active Abandoned
-
2016
- 2016-03-10 US US15/066,872 patent/US20160185725A1/en not_active Abandoned
-
2017
- 2017-06-23 JP JP2017123131A patent/JP2017160270A/ja not_active Withdrawn
- 2017-08-28 US US15/688,310 patent/US11124482B2/en active Active
-
2018
- 2018-12-04 HK HK18115513.6A patent/HK1256476A1/zh unknown
-
2019
- 2019-01-10 JP JP2019002497A patent/JP2019070015A/ja not_active Withdrawn
-
2020
- 2020-07-06 US US16/921,542 patent/US20200331860A1/en not_active Abandoned
- 2020-12-18 JP JP2020209919A patent/JP2021050233A/ja active Pending
-
2023
- 2023-11-29 JP JP2023201921A patent/JP2024023447A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU92508I2 (fr) | Cabozantinib et toutes les formes thérapeutiquement équivalentes qui en dérivent telles que protégées par le brevet de base, y compris les sels pharmacetuiquement acceptables | |
WO2006014325A3 (en) | C-met modulators and method of use | |
ATE543821T1 (de) | Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen | |
WO2004092196A3 (en) | Tie-2 modulators and methods of use | |
ATE381332T1 (de) | Tyrosinkinase-hemmer | |
WO2004006846A3 (en) | Receptor-type kinase modulators and methods of use | |
BR0306988A (pt) | Piridazinonas substituìdas como inibidores de p38 | |
ATE331514T1 (de) | Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase | |
ATE309241T1 (de) | Tyrosin kinase inhibitoren | |
DE60018782D1 (de) | Tyrosin kinase inhibitoren | |
ATE554087T1 (de) | Neue kinaseinhibitoren | |
WO2004091480A3 (en) | Tie-2 modulators and methods of use | |
ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
DE60113286D1 (de) | Oral aktive salze mit tyrosinkinaseaktivität | |
WO2005039506A3 (en) | P70s6 kinase modulators and method of use | |
WO2004083235A3 (en) | Tie-2 modulators and methods of use | |
ATE540951T1 (de) | Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren |